Third Rock Ventures
高管
查看带有其 35 名主要高管的组织结构图
Third Rock Ventures 搜索最多的简介
- Abbie Celniker, Partner, Formation, Development and Strategy
- Neil Exter, Partner, Formation, Development and Strategy
- Chris Robinson, Chief Talent Officer
高管在Third Rock Ventures变化
- Courtney Wallace已作为Venture Partner加入公司 (新闻发布的2024一月26号).
- Jigar Raythatha 曾任 Venture Partner, 现升职为 Partner (新闻发布的2024一月26号).
- Vyas Ramanan 曾任 Principal, 现升职为 Venture Partner (新闻发布的2024一月26号).
创建提醒
跟踪 Third Rock Ventures 的高管变动
基金
Third Rock Ventures 拥有 1,475 家竞争者，其中包括 Lloyds Development Capital (联合王国)、BlackRock (美国(美洲)) 和 WindRose Health Investors (美国(美洲))。
Popular M&A news in 基金
- Abrdn Private Equity Opportunities Trust将改名为Patria Capital Partners。 (公布2024四月30号).
- HMC Capital 已收购 StratCap (公布2024二月28号).
- Thomvest Ventures 刚刚宣布为 250 筹款数百万美元。 (公布2024一月17号).
基金 行业的其他推荐联系人
- Valor Equity Partners 企业 Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer
- Vanguard 企业 Mortimer Buckley - Chairman of the Board and Chief Executive Officer (retiring in Dec 2024)
- Caisse de Dépôt et Placement du Québec 企业 Jean-Marc Arbaud - President and Chief Executive Officer of CDPQ Infra
消息
Third Rock Ventures 的最新新闻稿
- Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 | Tango Therapeutics, Inc
- Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis | Pliant Therapeutics, Inc.
- Septerna Appoints Industry Veterans Bernard Coulie, M.D., Ph.D., and Shalini Sharp to its Board of Directors - Septerna
- Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis | Pliant Therapeutics, Inc.
- CARGO Therapeutics Announces Pricing of Initial Public Offering | CARGO Therapeutics, Inc.
- Terremoto Biosciences Closes $175 Million Series B Financing | Terremoto
- Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
- Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023 | Pliant Therapeutics, Inc.
- Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer | Pliant Therapeutics, Inc.
- Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) | Fulcrum Therapeutics
- View more press releases Close
通过电子邮件
